SG11202106582YA - Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 - Google Patents
Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2Info
- Publication number
- SG11202106582YA SG11202106582YA SG11202106582YA SG11202106582YA SG11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazopyridazine
- kinase
- inhibitors
- activin receptor
- imidazopyridine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782994P | 2018-12-20 | 2018-12-20 | |
| US201962935891P | 2019-11-15 | 2019-11-15 | |
| PCT/US2019/067403 WO2020132197A1 (en) | 2018-12-20 | 2019-12-19 | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106582YA true SG11202106582YA (en) | 2021-07-29 |
Family
ID=69467674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106582YA SG11202106582YA (en) | 2018-12-20 | 2019-12-19 | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11459329B2 (https=) |
| EP (1) | EP3898627A1 (https=) |
| JP (2) | JP7414827B2 (https=) |
| KR (1) | KR20210116488A (https=) |
| CN (2) | CN114787160B (https=) |
| AU (1) | AU2019401649B2 (https=) |
| BR (1) | BR112021011948A2 (https=) |
| CA (1) | CA3124088A1 (https=) |
| CL (1) | CL2021001656A1 (https=) |
| CO (1) | CO2021008117A2 (https=) |
| CR (1) | CR20210336A (https=) |
| EC (1) | ECSP21044843A (https=) |
| IL (2) | IL318278A (https=) |
| MA (1) | MA54551A (https=) |
| MX (1) | MX2021007426A (https=) |
| PE (1) | PE20220277A1 (https=) |
| PH (1) | PH12021551446A1 (https=) |
| SG (1) | SG11202106582YA (https=) |
| TW (2) | TWI852968B (https=) |
| WO (1) | WO2020132197A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124088A1 (en) * | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN115956081A (zh) | 2020-06-12 | 2023-04-11 | 因赛特公司 | 具有作为alk2抑制剂的活性的咪唑并哒嗪化合物 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| KR20240078812A (ko) | 2022-11-28 | 2024-06-04 | 계명대학교 산학협력단 | 신규한 pim 키나아제 억제제 및 이의 용도 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| SI1283839T1 (https=) | 2000-05-26 | 2005-08-31 | Schering Corp | |
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| PE20030739A1 (es) | 2001-11-30 | 2003-08-28 | Schering Corp | Antagonistas del receptor de adenosina a2a |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| JP2005343889A (ja) * | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| ATE482213T1 (de) * | 2004-11-04 | 2010-10-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| ME02372B (me) * | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| HUP0700395A2 (en) | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| ES2375425T3 (es) * | 2007-07-26 | 2012-02-29 | Novartis Ag | Compuestos org�?nicos. |
| BRPI0817434A2 (pt) * | 2007-10-17 | 2015-06-16 | Novartis Ag | Composto orgânicos |
| EP2453882A1 (en) * | 2009-07-14 | 2012-05-23 | Beth Israel Deaconess Medical Center, Inc. | Methods of increasing liver proliferation |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| EP2598505B1 (en) * | 2010-07-28 | 2015-03-18 | Bayer Intellectual Property GmbH | Substituted imidazo[1,2-b]pyridazines |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| CN103649093B (zh) | 2011-05-06 | 2017-07-07 | 拜耳知识产权有限责任公司 | 取代的咪唑并吡啶和咪唑并哒嗪及其用途 |
| KR102092988B1 (ko) * | 2012-09-28 | 2020-03-25 | 벤더르빌트 유니버시티 | 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들 |
| MX2015005375A (es) * | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| US9682983B2 (en) * | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| EP3854796A1 (en) * | 2016-08-17 | 2021-07-28 | Children's Hospital Medical Center | Imidazo[1,2-a]pyridine compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| JP2019533643A (ja) * | 2016-09-14 | 2019-11-21 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | Ｂｍｐシグナル伝達の阻害、その化合物、組成物および使用 |
| MX2019002951A (es) | 2016-09-15 | 2019-09-11 | Armstrong World Ind Inc | Sistema de techo con movimiento aereo. |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| EP3558990B1 (en) | 2016-12-22 | 2022-08-10 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| US20200054643A1 (en) | 2017-01-18 | 2020-02-20 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2018165569A1 (en) * | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods |
| CN109963854B (zh) | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| RU2019133646A (ru) * | 2017-03-30 | 2021-04-30 | Ф. Хоффманн-Ля Рош Аг | Изохинолины в качестве ингибиторов hpk1 |
| CU20200041A7 (es) | 2017-10-24 | 2021-03-11 | Bayer Ag | Amidas de imidazopiridina sustituidas |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| CN115956081A (zh) | 2020-06-12 | 2023-04-11 | 因赛特公司 | 具有作为alk2抑制剂的活性的咪唑并哒嗪化合物 |
-
2019
- 2019-12-19 CA CA3124088A patent/CA3124088A1/en active Pending
- 2019-12-19 TW TW108146732A patent/TWI852968B/zh active
- 2019-12-19 EP EP19848840.5A patent/EP3898627A1/en active Pending
- 2019-12-19 IL IL318278A patent/IL318278A/en unknown
- 2019-12-19 BR BR112021011948-5A patent/BR112021011948A2/pt unknown
- 2019-12-19 JP JP2021535854A patent/JP7414827B2/ja active Active
- 2019-12-19 CN CN201980092367.1A patent/CN114787160B/zh active Active
- 2019-12-19 TW TW113128182A patent/TW202504901A/zh unknown
- 2019-12-19 MA MA054551A patent/MA54551A/fr unknown
- 2019-12-19 AU AU2019401649A patent/AU2019401649B2/en active Active
- 2019-12-19 WO PCT/US2019/067403 patent/WO2020132197A1/en not_active Ceased
- 2019-12-19 IL IL284139A patent/IL284139B2/en unknown
- 2019-12-19 MX MX2021007426A patent/MX2021007426A/es unknown
- 2019-12-19 CN CN202510176623.2A patent/CN120208959A/zh active Pending
- 2019-12-19 KR KR1020217022783A patent/KR20210116488A/ko active Pending
- 2019-12-19 CR CR20210336A patent/CR20210336A/es unknown
- 2019-12-19 US US16/720,935 patent/US11459329B2/en active Active
- 2019-12-19 PE PE2021001046A patent/PE20220277A1/es unknown
- 2019-12-19 SG SG11202106582YA patent/SG11202106582YA/en unknown
-
2021
- 2021-06-18 PH PH12021551446A patent/PH12021551446A1/en unknown
- 2021-06-18 CL CL2021001656A patent/CL2021001656A1/es unknown
- 2021-06-21 CO CONC2021/0008117A patent/CO2021008117A2/es unknown
- 2021-06-21 EC ECSENADI202144843A patent/ECSP21044843A/es unknown
-
2022
- 2022-06-09 US US17/836,602 patent/US12030889B2/en active Active
-
2023
- 2023-12-28 JP JP2023222944A patent/JP7723068B2/ja active Active
-
2024
- 2024-05-22 US US18/671,477 patent/US20240309008A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106582YA (en) | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 | |
| ZA202005341B (en) | Inhibitors of activin receptor-like kinase | |
| ZA202000561B (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| IL261625B (en) | Inhibitors of menin-mll in bridged cycles and methods of use | |
| IL277183B1 (en) | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation | |
| EP3267996A4 (en) | Pyrazolopyrimidine inhibitors of irak4 activity | |
| SMT202200326T1 (it) | Composti imidazo[4,5-d]pirrolo[2,3-b]piridinici come inibitori di chinasi janus | |
| EP3268004A4 (en) | Pyrrolopyridazine inhibitors of irak4 activity | |
| EP3268006A4 (en) | Pyrrolotriazine inhibitors of irak4 activity | |
| IL255444B (en) | Tricyclic compounds and their uses as phosphodiesterase inhibitors | |
| PL3597649T3 (pl) | Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 | |
| IL265233B (en) | Spiro-cyclic inhibitors of the menin-mll interaction | |
| SG11202005264PA (en) | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor | |
| SI3177623T1 (sl) | Spojine 6,7-dihidropirazolo(1,5-a)pirazin-4(5H)-on in njihova uporaba kot negativni alosterični modulatorji receptorja MGLU2 | |
| IL267671A (en) | Pyrazolopyrimidine compounds and methods of their use | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| IL276312B1 (en) | Use of Alkoxypyrazoles as nitrification inhibitors | |
| SI3174883T1 (sl) | Spojine 6,7-dihidropirazolo(1,5-a)pirazin-4(5H)-on in njihova uporaba, kot negativni alosterični modulatorji receptorjev MGLU2 | |
| EP3907225A4 (en) | COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE | |
| IL290482A (en) | Salt and crystal forms of the activin receptor-like kinase inhibitor | |
| EP3313852A4 (en) | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors | |
| EP3183256A4 (en) | Substituted macrocycles useful as kinases inhibitors and methods of use thereof | |
| HUE067997T2 (hu) | Szubsztituált 2-tiazolinok mint nitrifikációs inhibitorok | |
| MA46176A (fr) | Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci | |
| HK40062276A (en) | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |